Back to Directory
Danuglipron
Metabolic & Weight ManagementOral small molecule GLP-1 agonist being developed by Pfizer.
Key Benefits
- ✓Oral administration
- ✓Weight loss
- ✓Glucose control
- ✓No injections needed
Dosing Information
Dosage Range
Under investigation
Frequency
Twice daily oral
Typical Duration
Development ongoing
Detailed Protocol
Under development as oral twice-daily tablet. Development pathway has had setbacks. Trials ongoing.
About Danuglipron
Danuglipron (PF-06882961) is a non-peptide oral GLP-1 receptor agonist. Designed for twice-daily oral dosing. Being developed by Pfizer for type 2 diabetes and obesity, though development has faced challenges.
Research Notes
Development has faced challenges with GI tolerability. Pfizer modified approach with extended-release formulation. Competing with other oral GLP-1 programs.
Potential Side Effects
- •Nausea and vomiting
- •High GI side effects led to modified approach
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.